The gene-editing market is moving fast, and it pays to get to know some of these companies.
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -550% and 72.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wave Life Sciences (WVE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...
AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).